149 related articles for article (PubMed ID: 35020170)
21. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Moeremans K; Annemans L
Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
24. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
Freeman K; Connock M; Cummins E; Gurung T; Taylor-Phillips S; Court R; Saunders M; Clarke A; Sutcliffe P
Health Technol Assess; 2015 Nov; 19(91):1-321, v-vi. PubMed ID: 26542268
[TBL] [Abstract][Full Text] [Related]
25. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
[TBL] [Abstract][Full Text] [Related]
30. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
32. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
33. Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
Ye M; Lu J; Yang F; Wu B
Biomed Res Int; 2018; 2018():9282646. PubMed ID: 30155484
[TBL] [Abstract][Full Text] [Related]
34. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis.
Yao J; Jiang X; You JHS
J Gastroenterol Hepatol; 2021 Sep; 36(9):2397-2407. PubMed ID: 33326123
[TBL] [Abstract][Full Text] [Related]
35. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
39. Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness.
Nair N; Kvizhinadze G; Blakely T
Value Health; 2016 Dec; 19(8):936-944. PubMed ID: 27987643
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
